Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Urelumab Phase 1 in Advanced Malignant Tumors
NCT02534506Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2015
- Primary completion
- Nov 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of urelumab in solid tumor, sponsored by Bristol Myers Squibb. Primary endpoints: Dose Limiting Toxicity at 60 days and Adverse Events at 60 days. Started Nov 2015; status: completed.
02
Drugs
urelumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02534506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02534506.